Clinical TrialJun 16, 2026, 08:31 AM
FibroBiologics Doses First Patients in Phase 1/2 DFU Clinical Trial
AI Summary
FibroBiologics, Inc. announced that the first patients have been dosed in its Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs). This marks a significant transition from laboratory science to clinical application for the investigational allogeneic fibroblast cell-based therapy. Concurrently, the company is advancing its manufacturing operations, having released drug product from its second good manufacturing practice (GMP) run and completed the first two batches of its third GMP run to support ongoing trial activity.
Key Highlights
- First patients dosed in FibroBiologics' Phase 1/2 clinical trial for CYWC628 in diabetic foot ulcers.
- Initial dosing for the trial took place during the week of June 1, 2026.
- Drug product from the second GMP manufacturing run has been released and shipped to Australia.
- FibroBiologics completed manufacturing of the first two batches of its third GMP run.
- CYWC628 is an investigational topically administered allogeneic fibroblast cell-based therapy.
- FibroBiologics holds over 270 issued and pending patents.
Price Impact
More from FBLG